Astrazeneca (AZN) Minority Interest (2009 - 2026)

Astrazeneca (AZN) has reported Minority Interest for 18 consecutive years, with $51.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Minority Interest fell 44.57% year-over-year to $51.0 million; the TTM figure through Mar 2026 stood at $51.0 million (down 44.57% YoY), while the FY2025 annual figure was $52.0 million, down 38.82% from the prior year.
• Minority Interest came in at $51.0 million for Q1 2026 at Astrazeneca, down from $52.0 million in the prior quarter.
• The five-year high for Minority Interest was $92.0 million in Q1 2025, with the low at $19.0 million in Q1 2022.
• Average Minority Interest over 5 years is $50.2 million, with a median of $51.0 million recorded in 2026.
• Across the five-year window, Minority Interest sank 88.1% in 2022 and soared 269.57% in 2024, its largest moves.
• Year by year, Minority Interest stood at $21.0 million in 2022, then gained by 9.52% to $23.0 million in 2023, then jumped by 269.57% to $85.0 million in 2024, then tumbled by 38.82% to $52.0 million in 2025, then dropped by 1.92% to $51.0 million in 2026.
• According to Business Quant data, Minority Interest over the past three periods registered $51.0 million, $52.0 million, and $83.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.